CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...